Key Highlights
•
The WHO plans to formally recognize steatotic liver disease (SLD) as a global non-communicable disease (NCD) at the 2026 World Health Assembly. This is a major step to ensure SLD gets the same public health focus and resources as other major NCDs like heart disease and cancer.
Source →
•
A simple mailed audit and feedback program for antibiotic prescribing in Canadian primary care was found to be cost-effective from a public payer perspective. This shows that low-cost, scalable interventions can help curb antibiotic overuse, a major driver of antimicrobial resistance.
Source →
•
A study of over 2,200 patients with cardiac amyloidosis found that nearly 40% had reduced or mildly reduced heart function, not just the preserved function it’s typically known for. This means doctors need to look for this condition across all types of heart failure, as it changes treatment and prognosis.
Source →
•
A modified dose of the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid) was shown to be safe and effective for patients with severe kidney impairment, including those on dialysis. This provides a crucial treatment option for a high-risk group that was previously excluded from using this medication.
Source →
•
US children exposed to neighborhood violence were significantly more likely to have delayed or skipped medical, dental, and mental health care due to cost. This highlights how social factors like violence exposure create major barriers to accessing essential preventive and acute healthcare for kids.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
